Effect of hemodialysis session on the dynamics of carnitine ester profile changes in l-carnitine pretreated end-stage renal disease patients

International Urology and Nephrology

Volumn 45, Issue 3, 2013, Pages 847-855

  Csiky, Botond ^a,b   Bene, Judit ^b   Wittmann, Istvan ^b   Sulyok, Endre ^c   Melegh, Bela ^b  

^a FMC Dialysis Center Pecs   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Acylcarnitines; Carnitine supplementation; End stage renal disease; Hemodialysis

Indexed keywords

ACYLCARNITINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITRIOL; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CARNITINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; IRON; POLYSULFONE;

ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; CARNITINE DEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LONG TERM CARE; LONGITUDINAL STUDY; MALE; SUPPLEMENTATION; THERAPY EFFECT;

ADULT; AGED; AGED, 80 AND OVER; CARDIOMYOPATHIES; CARNITINE; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERAMMONEMIA; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MUSCULAR DISEASES; RENAL DIALYSIS; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 84879501231     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0209-x     Document Type: Article

References (41)

1. Evans A (2003) Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 41:S13-S26
2. Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V (2003) Carnitine and hemodialysis. Am J Kidney Dis 41:S116-S122
3. Schreiber B (2005) Levocarnitine and dialysis: a review. Nutr Clin Pract 20:218-243
4. Hoppel C (2003) The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis 41:S4-S12
5. Melegh B, Sumegi B, Sherry AD (1993) Preferential elimination of pivalate with supplemental carnitine via formation of pivaloylcarnitine in man. Xenobiotica 23:1255-1261
6. Melegh B, Pap M, Morava E, Molnar D, Dani M, Kurucz J (1994) Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid. J Pediatr 125:317-321
7. Melegh B, Kerner J, Sandor A, Vinceller M, Kispal G (1987) Effects of oral L-carnitine supplementation in low-birth-weight premature infants maintained on human milk. Biol Neonate 51:185-193
8. Melegh B, Kerner J, Acsadi G, Lakatos J, Sandor A (1990) L-carnitine replacement therapy in chronic valproate treatment. Neuropediatrics 21:40-43
9. Vaz FM, Melegh B, Bene J, Cuebas D, Gage DA, Bootsma A, Vreken P, van Gennip AH, Bieber LL, Wanders RJ (2002) Analysis of carnitine biosynthesis metabolites in urine by HPLC-electrospray tandem mass spectrometry. Clin Chem 48:826-834
10. Calo LA, Pagnin E, Davis PA, Semplicini A, Nicolai R, Calvani M, Pessina AC (2006) Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 107:54-60
11. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yucel D (2006) Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant 21:3211-3214
12. Komlosi K, Havasi V, Bene J, Sule N, Pajor L, Nicolai R, Benatti P, Calvani M, Melegh B (2007) Histopathologic abnormalities of the lymphoreticular tissues in organic cation transporter 2 deficiency: evidence for impaired B cell maturation. J Pediatr 150:109-111
13. Guarnieri G, Biolo G, Vinci P, Massolino B, Barazzoni R (2007) Advances in carnitine in chronic uremia. J Ren Nutr 17:23-29
14. Evans AM, Faull R, Fornasini G, Lemanowicz EF, Longo A, Pace S, Nation RL (2000) Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther 68:238-249
15. Eknoyan G, Latos DL, Lindberg J (2003) Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis 41:868-876
16. Vacha GM, Corsi M, Giorcelli G, Iddio SD (1985) Serum and muscle L-carnitine levels in hemodialyzed patients, during and after long-term L-carnitine treatment. Curr Therapeut Res 37:505-516
17. Brass EP (1995) Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clin Ther 17:176-185
18. Calvani M, Benatti P, Mancinelli A, D'Iddio S, Giordano V, Koverech A, Amato A, Brass EP (2004) Carnitine replacement in end-stage renal disease and hemodialysis. Ann N Y Acad Sci 1033:52-66
19. Bellinghieri G, Savica V, Mallamace A, Di SC, Consolo F, Spagnoli LG, Villaschi S, Palmieri G, Corsi M, Maccari F (1983) Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 38:523-531
20. Leschke M, Rumpf KW, Eisenhauer T, Fuchs C, Becker K, Kothe U, Scheler F (1983) Quantitative assessment of carnitine loss during hemodialysis and hemofiltration. Kidney Int Suppl 16:S143-S146
21. Panzetta G, Bonadonna G, Giovene P, De GD (1985) Carnitine kinetics during dialysis. Evidence of unilateral transport from tissues to plasma. Nephron 41:230-234
22. Jackson JM, Lee HA (1996) L-carnitine and acetyl-L-carnitine status during hemodialysis with acetate in humans: a kinetic analysis. Am J Clin Nutr 64:922-927
23. Vernez L, Dickenmann M, Steiger J, Wenk M, Krahenbuhl S (2006) Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. Nephrol Dial Transplant 21:450-458
24. Reuter SE, Evans AM, Faull RJ, Chace DH, Fornasini G (2005) Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease. Ann Clin Biochem 42:387-393
25. Bene J, Komlosi K, Magyari L, Talian G, Horvath K, Gasztonyi B, Miheller P, Figler M, Mozsik G, Tulassay Z, Melegh B (2007) Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes. Br J Nutr 98:345-350
26. Bene J, Csiky B, Komlosi K, Sulyok E, Melegh B (2011) Dynamic adaptive changes of the serum carnitine esters during and after L-carnitine supplementation in patients with maintenance haemodialysis. Scand J Clin Lab Invest 71:280-286
27. Maeda K, Shinzato T, Kobayakawa H (1989) Effects of L-carnitine administration on short-chain fatty acid (acetic acid) and long-chain fatty acid metabolism during hemodialysis. Nephron 51:355-361
28. Girelli D, Azzini M, Olivieri O, Guarini P, Trevisan MT, Lupo A, Bernich P, Panzetta G, Corrocher R (1992) Red blood cells and platelet membrane fatty acids in non-dialyzed and dialyzed uremics. Clin Chim Acta 211:155-166
29. Sakurabayashi T, Takaesu Y, Haginoshita S, Takeda T, Aoike I, Miyazaki S, Koda Y, Yuasa Y, Sakai S, Suzuki M, Takahashi S, Hirasawa Y, Nakamura T (1999) Improvement of myocardial fatty acid metabolism through L-carnitine administration to chronic hemodialysis patients. Am J Nephrol 19:480-484
30. Siami G, Clinton ME, Mrak R, Griffis J, Stone W (1991) Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 57:306-313
31. Borum PR, Bennett SG (1986) Carnitine as an essential nutrient. J Am Coll Nutr 5:177-182
32. Violante S, Ijlst L, van Lenthe H, de Almeida IT, Wanders RJ, Ventura FV (2010) Carnitine palmitoyltransferase 2: new insights on the substrate specificity and implications for acylcarnitine profiling. Biochim Biophys Acta 1802:728-732
33. Furuno T, Kanno T, Arita K, Asami M, Utsumi T, Doi Y, Inoue M, Utsumi K (2001) Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem Pharmacol 62:1037-1046
34. Hebert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, Madore F (2001) Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis 38:1271-1276
35. Masse M, Hebert MJ, Troyanov S, Vigneault N, Sirois I, Madore F (2002) Soluble Fas is a marker of peripheral arterial occlusive disease in haemodialysis patients. Nephrol Dial Transplant 17:485-491
36. Troyanov S, Hebert MJ, Masse M, Vigneault N, Sirois I, Madore F (2003) Soluble Fas: a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis 41:1043-1051
37. Dalboni MA, Sardenberg C, Andreoli MC, Watanabe R, Canziani ME, Santos BF, Liangos O, Jaber BL, Draibe S, Cendoroglo M (2003) Soluble Fas: a novel marker of inflammation in uremia. Artif Organs 27:687-691
38. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270-1274
39. Moore KH, Dandurand DM, Kiechle FL (1992) Fasting induced alterations in mitochondrial palmitoyl-CoA metabolism may inhibit adipocyte pyruvate dehydrogenase activity. Int J Biochem 24:809-814
40. Gunal AI, Celiker H, Donder E, Gunal SY (1999) The effect of L-carnitine on insulin resistance in hemodialysed patients with chronic renal failure. J Nephrol 12:38-40
41. Arduini A (1992) Carnitine and its acyl esters as secondary antioxidants? Am Heart J 123:1726-1727